Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

Recruiting now

Conditions studied: Liver Cancer, Adult

In brief

The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.

Key facts

Study ID

NCT06777628

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

100

Starts

2024-09-15

Expected to finish

2028-10-15

Last updated by the study team

2025-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age ≥ 18 years
• diagnosis of HCC
• execution of laboratory tests and subsequent treatments and follow-up at our center.
• obtained written informed consent to the study participation

You may not qualify if…

• immune-related concomitant diseases
• HIV infection

Where it is running

• IRCCS-Azienda Ospedaliero-Universitaria di Bologna — Bologna, Laura Gramantieri, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.